研究单位:[1]Hebei Medical University Fourth Hospital河北医科大学第四医院
研究目的:
The purpose of this study is to assess time window, efficacy and safety of patients who receive anti-PD-1 antibody multimodal combination as first-line treatment of advanced solid tumor.